Physician profile
Irina Anshelevich
NPI 1235176462
$1,749.72
in general payments reported to CMS, 2019-2025
27 companies · $17.90 in 2025
The $17.90 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $167 · 2021: $155 · 2022: $444 · 2023: $533 · 2024: $34.88 · 2025: $17.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $259.53 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $211.81 | 2021-2023 | Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.65 | 2019-2022 | |
| Abbott Laboratories | $125.91 | 2022-2024 | Freestyle Libre |
| Glaxosmithkline, LLC. | $121.20 | 2019-2023 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $116.69 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $113.78 | 2019-2023 | Steglatro, Belsomra, Gardasil 9 |
| Novo Nordisk INC | $96.25 | 2021-2023 | Ozempic, Rybelsus |
| Almatica Pharma LLC | $72.13 | 2022-2023 | Gralise, Loreev Xr |
| Pfizer INC. | $54.73 | 2019-2022 | |
| Therapeuticsmd, INC. | $52.69 | 2019 | |
| Idorsia Pharmaceuticals US INC | $47.36 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $42.54 | 2019-2025 | Eohilia |
| Bayer Healthcare Pharmaceuticals INC. | $38.65 | 2023 | |
| Lilly USA, LLC | $31.19 | 2023 | Mounjaro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $26.32 | 2023 | Minimed 780g |
| Arbor Pharmaceuticals, INC. | $23.62 | 2020-2022 | |
| Allergan, INC. | $21.21 | 2020 | |
| Boston Scientific Corporation | $20.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.14 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.20 | 2024 | Farxiga |
| Neurocrine Biosciences, INC. | $14.63 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.26 | 2022 | |
| Hikma Pharmaceuticals USA | $13.66 | 2020 | |
| Ibsa Pharma INC. | $13.64 | 2022 | |
| Assertio Therapeutics, INC. | $13.60 | 2020 | |
| Ferring Pharmaceuticals INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Anshelevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.